Cryosite Ltd
ASX:CTE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.55
1.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Cryosite Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | AU |
Market Cap | 43.7m AUD |
Net Margin |
15%
|
Country | US |
Market Cap | 1.3T USD |
Net Margin |
9%
|
Country | US |
Market Cap | 196.3B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 170.3B USD |
Net Margin |
18%
|
Country | KR |
Market Cap | 66.5T KRW |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.6B CHF |
Net Margin |
9%
|
Country | US |
Market Cap | 38.5B USD |
Net Margin |
22%
|
Country | US |
Market Cap | 36.7B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 26.4B USD |
Net Margin |
21%
|
Country | US |
Market Cap | 23B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 22.3B USD |
Net Margin |
-36%
|
Cryosite Ltd
Glance View
Cryosite Ltd. engages in the provision of long term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-05-09. The firm operates through two segments, which include Clinical Trials and Biological Services Logistics, and Cord Blood and Tissue Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services to the clinical trial and research industry. The Cord Blood and Tissue Storage segment provides long-term storage for cord blood and tissue samples. The firm engages in clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution, and reverse logistics management.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cryosite Ltd's most recent financial statements, the company has Net Margin of 14.6%.